Literature DB >> 8219797

Biology and neurobiology of Borna disease viruses (BDV), defined by antibodies, neutralizability and their pathogenic potential.

H Ludwig1, K Furuya, L Bode, N Klein, R Dürrwald, D S Lee.   

Abstract

Borna disease viruses (BDV) isolated from more than 20 naturally infected horses, 2 sheep and a possible feline isolate were included in these studies. Most of these wild-type viruses were grown in rabbit cells. Specifically rabbit-adapted viruses establish persistent infection in immortalized cell lines of various animal species. Brain-, tissue culture-, and cell-free released viruses could all be neutralized with antibodies from naturally and experimentally infected animals (horse; hamster, rat, rabbit, mouse, and chicken), with highest titres in birds. Splenectomized rabbits, which were subsequently infected with BDV, efficiently produced high titres of neutralizing antibodies. All of the neutralizing sera and cerebrospinal fluids from infected animals inhibited tissue culture spread of BDV. Experimental infection and hyperimmunization induced antibodies directed against the major components of the soluble antigen (60, 40/38, 25 and 14.5 kD proteins). Analysis of the s-antigen complex with these sera and 6 stable monoclonal antibodies revealed that it consists of 40/38 and 25 kD proteins. Although each of these antibodies detected intracellular virus-specific structures they did not recognize outer plasma membrane antigens, showed no cross-reactivity, and had no neutralizing capacity. Unifying pathogenetic concepts of this neurotropic virus and its structural elements are discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8219797     DOI: 10.1007/978-3-7091-9300-6_10

Source DB:  PubMed          Journal:  Arch Virol Suppl        ISSN: 0939-1983


  23 in total

1.  Processing of the Borna disease virus glycoprotein gp94 by the subtilisin-like endoprotease furin.

Authors:  J A Richt; T Fürbringer; A Koch; I Pfeuffer; C Herden; I Bause-Niedrig; W Garten
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

2.  Borna disease virus: immunoelectron microscopic characterization of cell-free virus and further information about the genome.

Authors:  W Zimmermann; H Breter; M Rudolph; H Ludwig
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

Review 3.  Molecular biology of borna disease virus: prototype of a new group of animal viruses.

Authors:  J C de la Torre
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  Identification of the immunodominant H-2K(k)-restricted cytotoxic T-cell epitope in the Borna disease virus nucleoprotein.

Authors:  K Schamel; P Staeheli; J Hausmann
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Borna disease in a free-ranging lynx (Lynx lynx).

Authors:  M P Degiorgis; A L Berg; C Hârd Af Segerstad; T Mörner; M Johansson; M Berg
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

Review 6.  Borna disease virus infection, a human mental-health risk.

Authors:  Liv Bode; Hans Ludwig
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

7.  Sequence variability of Borna disease virus open reading frame II found in human peripheral blood mononuclear cells.

Authors:  M Kishi; Y Arimura; K Ikuta; Y Shoya; P K Lai; M Kakinuma
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  N-glycosylated protein(s) are important for the infectivity of Borna disease virus (BDV).

Authors:  R Stoyloff; T Briese; K Borchers; W Zimmermann; H Ludwig
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Neutralizing antibodies in Borna disease virus-infected rats.

Authors:  C G Hatalski; S Kliche; L Stitz; W I Lipkin
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  A functional role for neutralizing antibodies in Borna disease: influence on virus tropism outside the central nervous system.

Authors:  L Stitz; K Nöske; O Planz; E Furrer; W I Lipkin; T Bilzer
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.